QQQ
-6.78
396.69
-1.74%
BTC/USD
-6463.36
47137.69
-12.06%
DIA
-0.37
346.98
-0.11%
SPY
-4.16
461.56
-0.91%
TLT
+ 1.82
150.71
+ 1.19%
GLD
+ 1.39
163.85
+ 0.84%

Stifel Cautious On Aurora Cannabis Given 'Lack Of A Definitive Strategy' In US

June 6, 2019 10:19 am
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More
Stifel Cautious On Aurora Cannabis Given 'Lack Of A Definitive Strategy' In US

Cannabis stocks are getting more and more attention from Wall Street these days, and Aurora Cannabis Inc (NYSE:ACB) received its first coverage from Stifel on Thursday.

The Analyst

Stifel analyst W. Andrew Carter initiated coverage of Aurora with a Hold rating and a C$10 ($7.47) price target.

The Thesis

Despite impressive growth numbers projected in the next several years, Carter said Aurora’s international medical-use growth opportunities are limited outside of Canada and Germany.

“We are cautious on Aurora in the near-term given the company's reliance on the capital markets to execute upon its near-term business plans, the lack of a definitive strategy for entering the U.S. market, and we believe the slower development of the global medical opportunity will yield downside versus consensus estimates,” he wrote in a note.

Need more cannabis news? Check out all of our coverage here.

For now, Carter said Aurora has an enviable position as the No. 2 Canadian cannabis producer behind top Stifel pick Canopy Growth Corp (NYSE:CGC). He isn't convinced Aurora management fully appreciates the level of investment that will be required to defend that position as the market grows.

Aurora has also yet to secure partnerships with a global consumer or pharmaceutical company. However, the addition of investor Nelson Peltz as a strategic advisor should help remedy the situation, according to Carter.

Carter said Aurora’s valuation has upside only if it can maintain its Canadian market leadership position and its industry-leading margins over time. The company will also need to demonstrate it can be profitable.

Price Action

Aurora shares traded lower by 3 percent to $7.48 at time of publication Thursday.

Related Links:

Stifel: Canopy Growth Is The 'Best Investable Opportunity' In Cannabis

Analyst Likes Tilray In The Long Run, But Says Stock Is Overvalued Right Now

Photo courtesy of Aurora Cannabis.

For the latest in financial news, exclusive stories, memes follow Benzinga on Twitter, Facebook & Instagram. For the best interviews, stock market talk & videos, subscribe to Benzinga Podcasts and our YouTube channel.


Related Articles

Aurora Cannabis Analyst Lowers Price Target, Says Cannabis Company Needs 'Greater Financial Discipline'

Aurora Cannabis Analyst Lowers Price Target, Says Cannabis Company Needs 'Greater Financial Discipline'

What Are The Value Drivers For Aurora Cannabis? Analyst Opines Post Q1 Earnings

What Are The Value Drivers For Aurora Cannabis? Analyst Opines Post Q1 Earnings

After the market closed on Tuesday, Aurora Cannabis Inc. (NYSE: ACB) disclosed its financial and operational results for the first quarter of fiscal 2022. read more
What Will Drive Aurora Cannabis' Value Most? Analyst's Thoughts Ahead Of Q1 Earnings Report

What Will Drive Aurora Cannabis' Value Most? Analyst's Thoughts Ahead Of Q1 Earnings Report

Over the last year, Aurora Cannabis Inc. read more
Piper Sandler's Michael Lavery Shares Cannabis Industry Projections, Names 'The Real Key Catalyst To Watch'

Piper Sandler's Michael Lavery Shares Cannabis Industry Projections, Names 'The Real Key Catalyst To Watch'

The U.S. cannabis market has the potential to reach $115 billion by 2030, while last year regulated sales in the country have hit $17.5 billion, according to Michael Lavery, a director and senior research analyst covering consumer staples and cannabis for Piper Sandler. read more